Movement Alert｜ResMed Falls 5.08% in Regular Trading, Shares Retreat Despite Earnings and Guidance Beat

Market Focus10-30 22:11

On October 30, ResMed fell 5.08% in regular trading, trading at $237.26 per share, with turnover of $131 million.

The main catalyst in public information was the company’s latest fiscal first-quarter report: adjusted EPS came in at $2.91 versus market expectations of about $2.67 to $2.69, while revenue reached $1.42 billion, above the roughly $1.39 billion consensus. ResMed also guided fiscal 2027 non-GAAP EPS to $12.00-$12.25 on revenue of $5.75 billion-$5.85 billion, broadly above or in line with analyst expectations.

Even so, the stock moved lower in the session, indicating that trading direction was not synchronized with the otherwise solid fundamentals. Additional context showed a broker raised its price target to $250 from $215, while FactSet data cited an average analyst rating of overweight and a mean price target of $272.20.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment